News

Upon closing of the transaction, which has been unanimously approved by the Boards of Directors of both the companies, Allergan will receive $33.75bn in cash and Teva shares

Zerbaxa for injection (1.5g) is an antibacterial combination product for intravenous infusion consisting of the cephalosporin antibacterial drug ceftolozane sulfate and the beta-lactamase inhibitor tazobactam sodium. The positive

The recalled lots are as follows:Lot # Exp. Date Vial Size NDC# individual vials NDC# carton of 5 vials31317857B 8/2015 100 mL 0703-3019-11 0703-3019-1231317859B 12/2015 100 mL 0703-3019-11

"The expanded indication of Kyprolis provides patients with relapsed multiple myeloma a new therapeutic option, helping to address a real unmet need for this common blood cancer," said

Ad-RTS-hIL-12 is a novel gene therapy candidate for the controlled expression of IL-12, a critical protein for stimulating an anti-cancer T cell immune response. The FDA’s Office of

The CHMP’s positive opinion is based on results from three Phase 3 pivotal studies investigating the short- and long-term safety and efficacy of Intuniv in children and adolescents

The patent covers a method of treating eye conditions using EyeGate’s proprietary Dexamethasone Phosphate pharmaceutical formulation delivered by ocular iontophoresis. The patent is not limited to any particular

Of the total amount, Allergan will pay $460m upon closing of the deal, while $100m will be paid by 2016. The deal will also include potential research and

As part of the deal, Knight will be responsible or handling all regulatory and commercial activities for AzaSite in Canada. AzaSite 1% is a prescription sterile eye drop